188 filings
Page 2 of 10
8-K
n8glg3 ko
7 Feb 23
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
4:31pm
8-K
oa0o0hp3bf 0c
1 Feb 23
Patent is expected to provide additional intellectual property protection until 2040
4:46pm
8-K
iaa9i1 b4mgqs
20 Jan 23
Other Events
4:10pm
8-K
w3ght
4 Jan 23
Tenax Therapeutics Announces Reverse Stock Split
5:05pm
8-K
qe2988fim
11 Oct 22
Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral
8:31am
8-K
nfq0wpr0jnw k6wv
20 Sep 22
Other Events
4:30pm
8-K
baq5o
15 Sep 22
Tenax Therapeutics Announces the Evaluation of Strategic Alternatives
9:00am
8-K
1uxwupia
18 Aug 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
zou9nstfnc no645ydq
16 Jun 22
Entry into a Material Definitive Agreement
4:35pm
8-K
n4nx6tb1
10 Jun 22
Departure of Directors or Certain Officers
4:31pm
8-K
yzozw
23 May 22
Tenax Therapeutics Announces Successful
4:32pm
8-K
cgieukgrnkt20iuc
20 May 22
Tenax Therapeutics Announces Certain Securities and Nasdaq Disclosures
4:30pm
8-K
qy1pm
24 Mar 22
Other Events
8:15am
8-K
li5t q7omyj
18 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:33pm
8-K
38l3bgpq zk
31 Jan 22
Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors
4:29pm
8-K
5tqyxjng y8ty
28 Jan 22
Entry into a Material Definitive Agreement
4:16pm
8-K
ilc swh5p3
24 Jan 22
TENAX THERAPEUTICS January 2022 I Corporate Presentation www.tenaxthera.com NASDAQ TENX
4:16pm
8-K
r0kmy04oh
12 Jan 22
Tenax Therapeutics Granted U.S. Patent for the Subcutaneous
4:53pm
8-K
38ny mk7q9q0y5eu
5 Jan 22
Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs
7:41am
8-K
6m9v2535q05r 0gv
14 Oct 21
Departure of Directors or Certain Officers
4:31pm